TargetBeta
SLC5A2
solute carrier family 5 member 2 · also SGLT2 · Solute carrier family 5
6 programs in company-led studies act on SLC5A2, from 5 companies: 2 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| dapagliflozin | AstraZeneca | phase 4 | 13314 running | – | a judged reading |
| empagliflozinrule | Boehringer Ingelheim | phase 4 | 14210 running | – | NCIt |
| ertugliflozinrule | Merck | phase 4 | 221 running | – | ChEMBL |
| Enavogliflozinrule | Daewoong Pharmaceutical | phase 3 | 258 running | – | the studies' text |
| vicadrostat | Boehringer Ingelheim | phase 3 | 165 running | CYP11B2 | the company's pipeline |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 20 running | DPP4 | NCIt |
Conditions their studies are in
- Diabetes Mellitus, Type 2, 6 programs
- Heart Failure, 3 programs
- Renal Insufficiency, Chronic, 3 programs
- Diabetes Mellitus, Type 1, 2 programs
- Diabetic Nephropathies, 2 programs
- Diabetes Mellitus, 1 program
- Diabetes Mellitus, Lipoatrophic, 1 program
- Fatty Liver, 1 program
- Liver Diseases, 1 program
- Renal Insufficiency, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026empagliflozin · Boehringer Ingelheim · phase 4 · NCT07093476
- Dec 10, 2026dapagliflozin · AstraZeneca · phase 4 · NCT07222917
- Dec 11, 2026vicadrostat · Boehringer Ingelheim · phase 3 · NCT07845630
- Nov 2027Enavogliflozin · Daewoong Pharmaceutical · phase 3 · NCT07619833
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.